Orasis Pharmaceuticals submits NDA for novel eye drop for presbyopia treatment

Orasis Pharmaceuticals announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%). In the Phase 3 NEAR-1 and NEAR-2 clinical trials evaluating CSF-1, the primary and key secondary endpoints were met. The most common treatment-related...